2e+41 Stock Overview
PHAXIAM Therapeutics S.A., a biopharmaceutical company, focuses on developing treatments for resistant bacterial infections in France and the United States.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
+ 1 more risk
PHAXIAM Therapeutics S.A. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €2.82 |
| 52 Week High | €10.80 |
| 52 Week Low | €2.42 |
| Beta | 1.8 |
| 1 Month Change | -8.44% |
| 3 Month Change | -35.32% |
| 1 Year Change | -60.83% |
| 3 Year Change | -95.18% |
| 5 Year Change | n/a |
| Change since IPO | -98.72% |
Recent News & Updates
Recent updates
Shareholder Returns
| 2e+41 | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | 0% | -2.2% | 2.5% |
| 1Y | -60.8% | -25.2% | 6.0% |
Return vs Industry: 2E41 underperformed the German Biotechs industry which returned 26% over the past year.
Return vs Market: 2E41 underperformed the German Market which returned 6.2% over the past year.
Price Volatility
| 2e+41 volatility | |
|---|---|
| 2e+41 Average Weekly Movement | 8.7% |
| Biotechs Industry Average Movement | 5.2% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in DE Market | 10.4% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 2E41's share price has been volatile over the past 3 months.
Volatility Over Time: 2E41's weekly volatility has decreased from 17% to 9% over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2004 | 45 | Thibaut Fayet | www.phaxiam.com |
PHAXIAM Therapeutics S.A., a biopharmaceutical company, focuses on developing treatments for resistant bacterial infections in France and the United States. It develops eryaspase, which is in Phase 3 clinical development for the treatment of second-line pancreatic cancer, and in Phase 2 stage for the treatment of triple-negative breast cancer and second-line acute lymphoblastic leukemia patients. The company also engages in developing a portfolio of phages targeting resistant and dangerous bacteria, which together account for more than two-thirds of resistant hospital-acquired infections, including staphylococcus aureus, escherichia coli, and pseudomonas aeruginosa.
PHAXIAM Therapeutics S.A. Fundamentals Summary
| 2e+41 fundamental statistics | |
|---|---|
| Market cap | €17.86m |
| Earnings (TTM) | -€11.96m |
| Revenue (TTM) | €5.70m |
3.1x
P/S Ratio-1.5x
P/E RatioIs 2e+41 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 2e+41 income statement (TTM) | |
|---|---|
| Revenue | €5.70m |
| Cost of Revenue | €0 |
| Gross Profit | €5.70m |
| Other Expenses | €17.66m |
| Earnings | -€11.96m |
Last Reported Earnings
Sep 30, 2023
Next Earnings Date
Mar 20, 2024
| Earnings per share (EPS) | -1.97 |
| Gross Margin | 100.00% |
| Net Profit Margin | -209.79% |
| Debt/Equity Ratio | 41.3% |
How did 2e+41 perform over the long term?
See historical performance and comparison